Excellent presentation by Michael Hofman about PSMA ligands
Advanced Prostate Cancer Consensus Conference UroTeragLATAM PSMA conference - UCSF/UCLA/PCF/Urotoday
Urooncologia.arg

NEPC (Neuroendocrine PC) vs AVPC (Agressive Variants of PC) by Andrew Armstrong in Advanced Prostate Cancer Consensus Conference 2024
OncoAlert UroToday.com CLOC: Curso Latinoamericano de Oncología Clínica Urooncologia.arg

'Side effects usually occur earlier with iPARP treatment' Elena Castro Advanced Prostate Cancer Consensus Conference

What can we do in mCRPC after triplet therapy. Excellent presentation by Dr Karim Fizazi (Gustave Roussy) and unplublished data from PEACE-1

The challenge of management of patients with mHSPC and early progression on combination therapy by Christopher Sweeney, MBBS
Advanced Prostate Cancer Consensus Conference #APCCC24

persistencia de PSA 0,7ng y/o ALTO RIESGO con dos factores hay que tratar al pte, con PSA 0,2NG sin factores de riesgo se discute .
#SIHAYCONSENSO
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! Juan Pablo Sade Urooncologia.arg EAU Edu Platform UROONCO
UroTarget

Amazing presentation by Piet Ost about the role of RT in localized HRPC Advanced Prostate Cancer Consensus Conference
The #teamwork is the key

What's the role of DRE in PC diagnosis? Excellent presentation by Declan Murphy in Advanced Prostate Cancer Consensus Conference

🎯 Starting the Advanced Prostate Cancer Consensus Conference meeting with excellent Translational Prostate Cancer Symposium!! 😎 OncoAlert Yüksel Ürün 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Prostate Cancer Foundation silke gillessen

Terrific paper from Neeraj Agarwal, MD, FASCO Daniel Castellano et al in Clinical Cancer Research re: #abemaciclib in #metastatic #prostatecancer ... full article here: aacrjournals.org/clincancerres/…

UroTarget 2024!
31 de Octubre-1,2 de Noviembre 2024
Powered by Asociación Argentina de Oncología Clínica (AAOC) Urooncologia.arg

Taller de teragnostico en cáncer de prostata con Martín Angel en Post GU-GI #Bariloche
UroTarget UroTeragLATAM Urooncologia.arg Asociación Argentina de Oncología Clínica (AAOC)

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

#GUcancer Must read lecture! EV302 trial! 🦾🦾🦾nejm.org/doi/full/10.10… OncoAlert UroTarget UroToday.com blatam uro Eur Urol Focus Uromigos

In December 2023, part of the UroTarget team carried out the highest GU tumor board in the world in Cordón del Plata, Mendoza (4300mts-14100ft).
Daniel Castellano FLoscoMD Martín Angel Dr. Tomás Soulé Martin Richardet Gustavo Losco #mountains #mountainlife

EV-pembro vs. GC-nivo vs Javelin paradigm as firstline therapy for advanced #urothelialcarcinoma #bladdercancer : my opinion- EV (enfortumab vedotin)-pembro for most patients eligible for aggressive combination therapy, but consider 1) GC-nivo (once hopefully approved) for

@Urotarget 31 Oct, 1-2 Nov 2024
📍 Our goal is to bridge the gap between cutting-edge uro-oncology findings and the unique challenges faced in local medical practices.
🗓️ Save the date for this year's edition!
urotoday.com/video-lectures… a través de UroToday.com

Advances in #PrecisionMedicine rapidly transforming treatment options for #BladderCancer patients. Daniel Castellano Hospital Universitario 12 de Octubre discusses the importance of multidisciplinary approaches in patient care and research > bit.ly/3SvJ7yD